**DPH: Annual General Mandate 2024**

On May 27, 2024, Hai Phong Pharmaceutical Joint Stock Company announced General Mandate No. 80/NQ-CTCPDHPP as follows:

Article 1: Approve the report on production and business activities 2023 and the plan for 2024:

Results of economic targets in production and business activities in 2023.

|  |  |  |
| --- | --- | --- |
| No. | Targets | Annual Results (Unit: Million VND) |
| Unit | 2022  | 2023 | Rate (%) |
| 1 | Total revenue |  | 197.9 | 187.5 | 95 |
|  | -Production |  | 85.2 | 89.4 | 105 |
|  | -Domestic business |  | 112.7 | 98.1 | 87 |
| 2 | Payable to the state budget |  | 7,424 | 8,464 | 114 |
| 3 | Profit after tax |  | 22.810 | 25.950 | 113.8 |
| 4 | Payables to social insurance, health insurance, unemployment insurance |  | 6,532 | 6,563 | 100.4 |
| 5 | Average income |  | VND 7.5 million/month | VND 7.8 million/month | 104 |
| 6 | Investment |  | 4.750 | 6.209 | 130.7 |
| 7 | Dividend payment (% of charter capital) |  | 15% | 17% | 113.3 |

Financial targets for 2024:

1. Total revenue:
* In 2024: VND 200 billion

In which:

* Domestic business: VND 110 billion
* Industrial production: VND 90 billion
1. Payables to the State budget: Same as in 2023
2. Profit after tax: Increase as in 2023
3. Average income: VND 8,000,000/month
4. Dividend payment rate: 17%/year.
5. Collect and pay social insurance, health insurance, and unemployment insurance fully and promptly.

Article 2: Approve the Report on appraisal of production and business results, financial and accounting data in 2023 and report on activities of the Supervisory Board in 2023.

Article 3: Approve the Report on remuneration of the Board of Directors and the Supervisory Board in 2023, the remuneration plan for members of the Board of Directors and the Supervisory Board in 2024.

Article 4: Approve the Report on the activities of the Board of Directors in 2023;

Article 5: The Meeting approves the dividend payment plan for 2023 as follows: 17%/year.

* Institutional shareholder (Hai Phong Pharmaceutical Company Limited): 350,000 shares; amount: VND 595,000,000
* For individual shareholders: 2,650,000 shares; amount: VND 4,505,000,000.
* The total amount of dividends paid to the depository organization is: VND 3,736,895,205 (Shareholders who have deposited dividends at depository institutions)
* The amount of dividends paid at the Company (For non-deposited shareholders) is: VND 571,426,100 (Shareholders receive money at the Company's Accounting Department)
* Plan for 2024: Expected dividend payment 2024: 17%

Article 6: Agree to amend the charter, supplement the business lines to the Company and its branches and terminate the operation of An Lao Pharmacy Branch.

Article 7: Approve upgrading and expanding investment in additional vial filling machines for the eye factory, increasing production output by 120% -150%.

Article 8: Submit to the General Meeting of Shareholders for approval of assigning the Board of Directors to evaluate the effectiveness of all business locations of the Company that are leased from the State. If business locations or business associations are ineffective, the Board of Directors has the sole discretion to decide to handle in the following forms: Request to purchase businesses to use, liquidate or return the rental rights to the State after recovering the costs invested in repairs to reduce difficulties and bring economic efficiency to the Company.

Article 9: Approve the operating regulations of the Board of Directors and the Supervisory Board according to Decree No. 71/2017 of the Government.

After 18 years of operation as a Joint Stock Company, shareholders are excited and confident in the stability and development of the Company, although there are still many difficulties ahead, the Company strives to implement the Ministry of Health's roadmap to meet GPs standards and moving towards upgrading and expanding the eye drop factory project.

The Company's headquarters area and the headquarters of Pharmacy branches all meet Good Distribution Practices (GDP), currently pharmacies are actively investing in upgrading the remaining drug-selling locations to meet Good Pharmacy Practices (GPP) standards.

To achieve the Company's development goals, in 2024, the Company's leaders set some basic socio-economic targets as follows:

1. Total revenue: VND 200 billion

In which: Domestic business VND 110 billion

Industrial production: VND 90 billion

1. Payables to the State budget: Same as in 2023
2. Profit after tax: Increased by 10%
3. Average income: VND 8,000,000/person/month.
4. Dividend payment rate: 17% per year
5. Collecting and paying social insurance, health insurance, and unemployment insurance fully and promptly.
6. Payment of remuneration for the Board of Directors and the Supervisory Board in 2024 is equal to 2023:
* Chair of the Board of Directors: Rate of 2.0
* Vice Chair of the Board of Directors: Rate of 1.5
* Members of the Board of Directors: Rate of 1.0
* Chief of the Supervisory Board: Rate of 1.0
* Member of the Supervisory Board: Rate of 0.75

The Annual General Meeting of Shareholders 2024 of Hai Phong Pharmaceutical Joint Stock Company assigned the Company's Board of Directors to implement this General Mandate with a specific agenda and measures to successfully carry out the set tasks.

All for the development of the Company, for the lives of Employees, the Board of Directors, The Company's Board of Directors asks all employees and shareholders of the Company, with a sense of responsibility and their working positions, to try to contribute their best to make Hai Phong Pharmaceutical Joint Stock Company stable, sustainable and developing.